IL245751B - Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment - Google Patents

Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment

Info

Publication number
IL245751B
IL245751B IL245751A IL24575116A IL245751B IL 245751 B IL245751 B IL 245751B IL 245751 A IL245751 A IL 245751A IL 24575116 A IL24575116 A IL 24575116A IL 245751 B IL245751 B IL 245751B
Authority
IL
Israel
Prior art keywords
synbiotics
responsiveness
chemotherapy
pro
marker
Prior art date
Application number
IL245751A
Other languages
English (en)
Hebrew (he)
Other versions
IL245751A0 (en
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Agronomique Inst Nat Rech
Univ Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave, Agronomique Inst Nat Rech, Univ Paris Sud filed Critical Inst Nat Sante Rech Med
Publication of IL245751A0 publication Critical patent/IL245751A0/en
Publication of IL245751B publication Critical patent/IL245751B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL245751A 2013-11-21 2016-05-19 Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment IL245751B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907076P 2013-11-21 2013-11-21
EP13306597.9A EP2876167A1 (en) 2013-11-21 2013-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
PCT/IB2014/066249 WO2015075688A1 (en) 2013-11-21 2014-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment

Publications (2)

Publication Number Publication Date
IL245751A0 IL245751A0 (en) 2016-07-31
IL245751B true IL245751B (en) 2019-08-29

Family

ID=49680948

Family Applications (2)

Application Number Title Priority Date Filing Date
IL245751A IL245751B (en) 2013-11-21 2016-05-19 Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment
IL268526A IL268526B (en) 2013-11-21 2019-08-05 Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL268526A IL268526B (en) 2013-11-21 2019-08-05 Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment

Country Status (13)

Country Link
US (2) US10646521B2 (enExample)
EP (2) EP2876167A1 (enExample)
JP (2) JP6662775B2 (enExample)
KR (1) KR102464342B1 (enExample)
CN (1) CN106170557B (enExample)
AU (1) AU2014351348B2 (enExample)
CA (1) CA2931363C (enExample)
DK (1) DK3071709T3 (enExample)
ES (1) ES2764282T3 (enExample)
IL (2) IL245751B (enExample)
PT (1) PT3071709T (enExample)
SG (1) SG10201803877YA (enExample)
WO (1) WO2015075688A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
HK1253064A1 (zh) * 2015-06-01 2019-06-06 The University Of Chicago 通过操纵共生微生物菌群对癌症的治疗
EP3130680A1 (en) * 2015-08-11 2017-02-15 Universitat de Girona Method for the detection, follow up and/or classification of intestinal diseases
DK4186927T3 (da) 2015-10-21 2025-06-10 Ose Immunotherapeutics Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
MA41013A (fr) * 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN106011281B (zh) * 2016-07-19 2019-04-23 浙江大学 肠道分节丝状菌鞭毛蛋白的检测方法
SG11201901726QA (en) * 2016-09-16 2019-03-28 Ubiome Inc Method and system for panel characterizations
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
EP3559257A1 (en) * 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
US11723935B2 (en) 2017-02-06 2023-08-15 New York University Methods and compositions for treating and diagnosing pancreatic cancers
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
BR112020002212A2 (pt) * 2017-08-10 2020-07-28 4D Pharma Research Limited composições compreendendo cepas bacterianas
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
EP3505177A1 (en) * 2017-12-29 2019-07-03 Institut Gustave Roussy Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
CN107904298A (zh) * 2017-12-29 2018-04-13 苏州普瑞森基因科技有限公司 一种用于分析肠道微生物的试剂盒及其应用
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
JP2021534091A (ja) * 2018-08-05 2021-12-09 ダ・ヴォルテッラ 抗がん剤の有効性を改善する方法
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
EP3629023A1 (en) * 2018-09-28 2020-04-01 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
AU2019384816A1 (en) 2018-11-21 2021-06-24 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
KR20210111254A (ko) * 2018-11-30 2021-09-10 캐리스 엠피아이, 아이엔씨. 차세대 분자 프로파일링
CN113166815B (zh) * 2019-02-22 2024-06-11 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
EP3950929A4 (en) * 2019-03-28 2023-01-04 CJ Bioscience, Inc. FAECALIBACTERIUM SP. MICROBE AND ANTI-CANCER COMPOSITION WITH IT
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微（深圳）生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
AU2020269080A1 (en) * 2019-05-08 2021-12-16 Megan BARNET Cancer stratification and treatment based on inhibition of NOD-2
US12685743B2 (en) 2019-10-01 2026-07-21 New York University Methods and compositions for treating and diagnosing pancreatic cancers
KR20220116438A (ko) * 2019-11-01 2022-08-23 유티아이 리미티드 파트너쉽 암 치료를 위한 미생물총 및 대사산물의 힘 활용
US20230002502A1 (en) * 2019-11-26 2023-01-05 South Australian Health And Medical Research Institute Limited Methods and products for reducing side effects associated with use of immune agonist antibodies
IL293489A (en) * 2019-12-02 2022-08-01 Caris Mpi Inc predictor of pan-cancer platinum response
CN114832088B (zh) * 2022-05-19 2026-04-14 李臻 拉瑞唑来多肽在制备缓解阿霉素心脏毒性药物中的用途
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116287355A (zh) * 2023-05-12 2023-06-23 中国医学科学院北京协和医院 上消化道肿瘤化疗疗效及不良反应的肠道菌群预测模型
CN116687981A (zh) * 2023-07-21 2023-09-05 中山大学附属第六医院 一种益生菌混合制剂在制备缓解奥沙利铂化疗毒副作用制品中的应用及药物
CN117237952B (zh) * 2023-11-15 2024-02-09 山东大学 基于免疫地形图的染色病理切片细胞分布标注方法及系统
CN120682997B (zh) * 2025-06-23 2026-05-05 佳木斯大学 一株副格氏乳杆菌及其在防治肝癌的产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08295631A (ja) 1995-02-27 1996-11-12 Nichinichi Seiyaku Kk 制癌増強剤
JPH1029946A (ja) * 1996-07-15 1998-02-03 Nichinichi Seiyaku Kk 液性免疫回復剤
TW200904340A (en) * 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
WO2010033425A2 (en) * 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
JP2012502998A (ja) 2008-09-19 2012-02-02 ネステク ソシエテ アノニム 癌性腫瘍からの骨髄毒性を阻止又は軽減するための栄養支援
JP5717116B2 (ja) * 2008-12-22 2015-05-13 学校法人昭和大学 抗原特異的ヒトＴｈ１７細胞を調整する方法
WO2011131472A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Also Published As

Publication number Publication date
KR102464342B1 (ko) 2022-11-08
WO2015075688A1 (en) 2015-05-28
AU2014351348A1 (en) 2016-06-09
CA2931363C (en) 2023-07-18
EP3071709A1 (en) 2016-09-28
EP3071709B1 (en) 2019-12-25
AU2014351348B2 (en) 2020-12-03
IL268526B (en) 2022-02-01
JP2016539119A (ja) 2016-12-15
JP2020050664A (ja) 2020-04-02
CA2931363A1 (en) 2015-05-28
US10646521B2 (en) 2020-05-12
KR20160079122A (ko) 2016-07-05
US20160303172A1 (en) 2016-10-20
SG10201803877YA (en) 2018-06-28
IL245751A0 (en) 2016-07-31
ES2764282T3 (es) 2020-06-02
PT3071709T (pt) 2020-01-17
EP2876167A1 (en) 2015-05-27
JP6662775B2 (ja) 2020-03-11
DK3071709T3 (da) 2020-03-16
CN106170557B (zh) 2020-08-21
CN106170557A (zh) 2016-11-30
US11344586B2 (en) 2022-05-31
IL268526A (en) 2019-09-26
US20200360449A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
IL268526B (en) Microbiome composition as a marker of reactivity to chemotherapy, and the use of microbial modulators (pre-, pro- or symbiotic) to improve the effectiveness of cancer treatment
AU2014310479B2 (en) Novel adsorbent composition and use thereof
EP3030302A4 (en) Improvements to flow therapy
EP3033424A4 (en) Compositions and methods for modulating rna
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
IL241352A0 (en) Compounds of pyruvate kinase plants, preparations containing them and their uses
EP3060041A4 (en) Prostacyclin compounds, compositions and methods of use thereof
EP3079683A4 (en) Methods to treat lymphoplasmacytic lymphoma
EP3088426A4 (en) Compound containing mesogenic group, and mixture, composition, and optically anisotropic body using said compound
EP3033091A4 (en) Method and compositions for treating cancer using probiotics cross-reference to related application
PT3524680T (pt) Composições e métodos para modular a expressão de ttr
IL238568A0 (en) Antibodies specific to tumor factor b derived from blood platelets, compositions containing them and their use
EP3007695A4 (en) Compositions and methods for treating anemia
EP3049073A4 (en) Compositions and method for destabilizing, altering, and dispersing biofilms
EP3079682A4 (en) Methods to treat lymphoplasmacytic lymphoma
IN2014DN09412A (enExample)
EP3041841A4 (en) Triazolopyridine compounds, compositions and methods of use thereof
EP2983678A4 (en) Anti-microbial composition
EP2832346A4 (en) AQUEOUS DISPERSED COMPOSITION
EP3055287A4 (en) Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
CA2875305C (en) Fbxo3 inhibitors
EP3090749A4 (en) Nutrient composition having lipid metabolism-improving action
EP2965808A4 (en) OXYGEN ABSORBING COMPOSITION
EP3071534A4 (en) Fertiliser composition
EP3010504A4 (en) Methods and compositions to treat cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed